Biochemical mechanisms of cyclosporine neurotoxicity

Molecular Interventions

Volumn 4, Issue 2, 2004, Pages 97-107

  Serkova, Natalie J ^a   Christians, Uwe ^a   Benet, Leslie Z ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; GLUCOCORTICOID; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

AMNESIA; ANXIETY DISORDER; APHASIA; ATAXIA; BIOCHEMISTRY; BRAIN EDEMA; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN PROTECTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLAR ATAXIA; CEREBELLUM HEMORRHAGE; CEREBRAL BLINDNESS; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DELUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; DRUG TOXICITY; ENERGY METABOLISM; EPILEPTIC DISCHARGE; GRAFT REJECTION; HALLUCINATION; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LACTIC ACIDOSIS; LEUKOENCEPHALOPATHY; METABOLIC ENCEPHALOPATHY; MITOCHONDRIAL ENCEPHALOPATHY; MITOCHONDRIAL RESPIRATION; MUSCLE WEAKNESS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGAN TRANSPLANTATION; OXYGEN TENSION; PARESTHESIA; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; RAT; REPERFUSION INJURY; RESTLESSNESS; REVIEW; SEIZURE; STROKE; SYMPTOMATOLOGY; TREMOR; VASOCONSTRICTION; VASOSPASM; WHITE MATTER;

ANIMALS; BRAIN; CYCLOSPORINE; ENERGY METABOLISM; GRAFT REJECTION; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MITOCHONDRIAL ENCEPHALOMYOPATHIES; NEUROTOXICITY SYNDROMES; ORGAN TRANSPLANTATION;

EID: 2342560435     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.2.7     Document Type: Review

References (93)

1. Allison, A.C. Immunosuppressive drugs: The first 50 years and glance forward. Immunopharmacology 47, 63-83 (2000).
2. Helderman, J.H., Bennett, W.M., Cibrik, D.M., Kaufman, D.B., Klein, A., and Takemoto, S.K. Immunosuppression: Practice and trends. Am. J. Transplant. 3, 41-52 (2003).
3. Schreiber, S.L. and Crabtree, G.R. The mechanism of action of cyclosporin A and FK506. Immunology Today 13, 136-142 (1992).
4. Dunn, C.J., Wagstaff, A.J., Perry, C.M., Plosker, G.L., and Goa, K.L. Cyclosporine: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 61, 1957-2016 (2001).
5. Kahan, B.D. Cyclosporine. N. Engl. J. Med. 321, 1725-1738 (1989).
6. Calne, R. Y., Rolles, K., Thiru, S. et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 2, 1033-1036 (1979).
7. Gijtenbeek, J.M., Van Den Bent, M.J., and Vecht, C.J. Cyclosporine neurotoxicity: A review. J. Neurol. 246, 339-346 (1999).
8. Hauben, M. Cyclosporine neurotoxicity. Pharmacotherapy 16, 576-583 (1996).
9. Wijdicks, E.F.M. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 7, 937-942 (2001).
10. Folbergrova, J., Li, P.A., Uchino, H., Smith, M.L., and Siesjö, B.K. Changes in the bioenergetic state of rat hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects. Exp. Brain Res. 114, 44-50 (1997).
11. Bernardi, P., Vassanelli, S., Veronese, P., Colonna, R., Szabo, I., and Zoratti, M. Modulation of the mitochondrial permeability transition pore. Effect of protons and divalent cations. J. Biol. Chem. 267, 2934-2939 (1994).
12. Serkova, N., Brand, A., Christians, U., and Leibfritz, D. Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy. Biochim. Biophys. Acta 1314, 93-104 (1996).
13. Serkova, N., Christians, U., Flögel, U., Pfeuffer, J., and Leibfritz, D. Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem. Res. Toxicol. 10, 1359-1363 (1997).
14. Serkova, N., Litt, L., James, T.L., Sadee, W., Leibfritz, D., Benet, L.Z., and Christians, U. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J. Pharmacol. Exp. Ther. 289, 800-806 (1999).
15. Serkova, N., Litt, L., Leibfritz, D., Hausen, B., Morris, R.E., James, T.L., Benet, L. Z., and Christians, U. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br. J. Pharmacol. 129, 485-492 (2000).
16. Serkova, N., Jacobsen, W., Niemann, C. U., Litt, L., Benet, L.Z., Leibfritz, D., and Christians, U. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br. J. Pharmacol. 133, 875-885 (2001).
17. Serkova, N., Donohoe, P., Gottschalk, S. et al. Comparison of the effects of cyclosporin A on the metabolism of perfused rat brain slices during normoxia and hypoxia. J. Cereb. Blood Flow Metab. 22, 342-352 (2002).
18. Groth, C. G., Bäckman, L., Morales, J. M. et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 67, 1036-1042 (1999).
19. Kreis, H., Cisterne, J. M., Land, W. et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69, 1252-1260 (2000).
20. Berden, J.H.M., Hottsma, A.J., Merx, J.L., and Keyser, A. Severe central-nervous-system toxicity associated with cyclosporine. Lancet 2, 219-220 (1985).
21. Kurzendorf, U., Brockmoller, J., Jochimsen, F., Keller, F., Walz, G., and Offermann, G. Cyclosporin metabolites and central nervous system toxicity. Lancet 1, 1223-1224 (1988).
22. Hawley, C.M., Rigby, R.J., Boyle, R.S., and Petrie, J.J.B. Onset of dialysis encephalopathy in cyclosporine-treated renal allograft recipients. Am. J. Kidney Dis. 15, 364-368 (1990).
23. Scheinman, S.J., Reinitz, E.R., Petro, G., Schwartz, R.A., and Szmalc, F.S. Cyclosporine central neurotoxicity following renal transplantation. Transplantation 49, 215-216 (1990).
24. Rodriguez, E., Delucci, A., and Cano, F. Neurotoxicity caused by cyclosporin A in renal transplantation in childern. Rev. Med. Chil. 120, 300-303 (1992).
25. Jeruss, J., Braun, S.V., Reese, J.C., and Guillot, A. Cyclosporine-induced white and grey matter central nervous system lesions in a pediatric renal transplant patient. Pediatr. Transplant. 2, 45-50 (1998).
26. Adams, D.H., Gunson, B., Honigsberger, L., Buckels, J., Ponsford, S., Boon, A., Williams, A., Elias, E., and McMaster, P. Neurological complications following liver transplantation. Lancet 1, 949-952 (1987).
27. De Groen, P.C., Aksamit, A.J., Rakela, J., Forbes, G.S., and Krom, R.A.F. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N. Engl. J. Med. 317, 861-866 (1987).
28. Vogt, D.P., Lederman, R.J., Carey, W.D., and Broughan, T.A. Neurologic complications of liver transplantation. Transplantation 45, 1057-1061 (1988).
29. Wilson, S.E., De Groen, P.C., Aksamit, A.J., Wiesner, R.H., Garrity, J.A., and Krom, R.A.F. Cyclosporin A-induced reversible cortical blindness. J. Clin. Neuroophthalmol. 8, 215-220 (1988).
30. Belli, L.S., De Carlis, L., Romani, F. et al. Dysarthria and cerebellar ataxia: Late occurrence of severe neurotoxicity in a liver transplant recipient. Transplant Int. 6, 176-178 (1993).
31. Moreno, E., Gomez, S.R., Gonzales, I., Loinaz, C., Garcia, I., and Perez, A. Neurologic complications in liver transplantation. Acta Neurol. Scand. 87, 25-31 (1993).
32. Wijdicks, E.F., Wiesner, R.H., and Krom, R.A.F. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 45, 1962-1964 (1995).
33. Colombani, P.M., Lau, H., Prabhakaran, K., Maley, W., Wise, B., Schwarz, K., and Klein, A. Cumulative experience with pediatric living related liver transplantation. J. Pediatr. Surg. 35, 9-12 (2000).
34. Guarino, M., Stracciari, A., Pazzaglia, P., Sterzi, R., Santilli, I., Donato, F., and D'Alessandro, R. Neurological complications of liver transplantation. J. Neurol. 243, 137-142 (1996).
35. Cooper, D.K., Novitzky, D., Davis, L., Huff, J.E., Parker, D., Schlesinger, R., Sholer, C., and Zuhdi, N. Does central nervous system toxicity occur in transplant patients with hypocholesterolemia receiving cyclosporine? J. Heart Transplant. 8, 221-224 (1989).
36. Drachman, B.M., DeNofrio, D., Acker, M.A., Galetta, S., and Loh, E. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: A case report and review of the literature. J. Heart Lung Transplant. 15, 1158-1164 (1996).
37. Hughes, R.L. Cyclosporine related central nervous system toxicity in cardiac transplantation. N. Engl. J. Med. 323, 420-421 (1993).
38. Lane, R.J.M., Roche, S.W., Leung, A.A.W., Greco, A., and Lange, L.S. Cyclosporine neurotoxicity in cardiac transplant recipients. J. Neurol. Neurosurg. Psychiatry 51, 1434-1437 (1988).
39. Mavroudakis, N. and De Beyl, D.Z. Cyclosporine neurotoxicity in cardiac transplant recipient. J. Neurol. Neurosurg. Psychiatry 52, 813 (1989).
40. McManus, R.P., O'Hair, D.P., Schweiger, J., Beitzinger, J., and Siegel, R. Cyclosporine-associated central neurotoxicity after heart transplantation. Ann. Thorac. Surg. 53, 325-327 (1992).
41. Truwit, C.L., Denaro, C.P., Lake, J.R., and DeMarco, T. MR imaging of reversible cyclosporin A-induced neurotoxicity. Am. J. Neuroradiol 12, 651-659 (1991).
42. Nussbaum, E.S., Maxwell, R.E., Bitterman, P.B., Hertz, M.I., Bula, W., and Latchaw, R.E. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. J. Neurosurg. 82, 1068-1070 (1995).
43. Goldstein, L.S., Haug, M.T., Perl, J., Perl, M.K., Maurer, J.R., Arroglia, A.C., and Mahta, A.C. Central nervous system complications after lung transplantation. J. Heart Lung Transplant. 17, 185-191 (1998).
44. Tirdel, G.B., Girgis, R., Fishman, R.S., and Theodore, J. Metabolic myopathy as a cause of the exercise limitation in lung transplant recipients. J. Heart Lung Transplant. 17, 1231-1237 (1998).
45. Bartynsky, W.S., Grabb, B.C., Zeigler, Z., Lin, L., and Andrews, D.F. Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity. J. Comput Assist. Tomogr. 21, 872-880 (1997).
46. Gopal, A.K., Thorning, D.R., and Back, A.L. Fatal outcome due to cyclosporine neurotoxicity with associated pathological findings. Bone Marrow Transplant. 23, 191-193 (1999).
47. Joss, D.V., Barrett, A.J., Kendra, J.R., Lucas, C.F., and Desai, S. Hypertension and convulsion in children receiving cyclosporin A. Lancet 1, 906 (1982).
48. Pace, M.T., Slovis, T.L., Kelly, J.K., and Abella, S.D. Cyclosporin A toxicity: MRI appearance of the brain. Pediatr. Radiol. 25, 180-183 (1995).
49. Reece, D.E., Frei-Lahr, D.A., Shepherd, J.D., Dorovini-Zis, K., Gascoyne, R.D., and Graeb, D.A. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 8, 393-401 (1991).
50. Rubin, A.M. and Kang, H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 37, 1072-1076 (1987).
51. Rubin, A.M. Transient cortical blindness and occipital seizures with cyclosporine toxicity. Transplantation 47, 572-573 (1989).
52. Shah, A.K. Cyclosporine A neurotoxicity among bone marrow transplant recipients. Clin. Neuropharmacol. 22, 67-73 (1999).
53. Thompson, C.B., Sullivan, K.M., June, C.H., and Thomas, E.D. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2, 1116-1120 (1984).
54. Humphreys, T.R. and Leyden, J.L. Acute reversible central nervous system toxicity associated with low-dose cyclosporine therapy. J. Am. Acad. Dermatol. 29, 490-492 (1993).
55. Porges, Y., Blumen, S., Fireman, Z., Sternberg, A., and Zamir, D. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am. J. Ophthalmol. 126, 607-608 (1998).
56. Martinez, A.J. The neuropathology of organ transplantation: Comparison and contrast in 500 patients. Pathol. Res. Pract. 194, 473-486 (1998).
57. Gleeson, J.G., DuPlesis, A.J., Barnes, P.D., and Riviello, J.J. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: Clinical features and risk of seizure recurrence. J. Child Neurol. 13, 336-344 (1998).
58. Sheth, T.N., Ichise, M., and Kucharczyk, W. Brain perfusion imaging in asymptomatic patients receiving cyclosporin. Am. J. Neuroradiol. 20, 853-856 (1999).
59. Deierhoi, M.H., Kalayoglu, M., Sollinger, H.W., and Belzer, F.O. Cyclosporine neurotoxicity in liver transplant recipients: Report of three cases. Transplant. Proc. 20, 116-118 (1988).
60. Monteiro, L., Almeido-Rinto, J., Rocha, N., Lopes, G., and Rocha, J. Case report: Cyclosporin A-induced neurotoxicity. Br. J. Radiol. 66, 271-272 (1993).
61. Edwards, L.L., Wszolek, Z.K., and Normand, M.M. Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Acta Neurol. Scand. 92, 423-429 (1995).
62. Jansen, O., Krieger, D., Krieger, S., and Sartor, K. Cortical Hyperintensity on proton density-weighted images: An MR sign of cyclosporine-related encephalopathy. Am. J. Neuroradiol. 17, 337-344 (1996).
63. Schwartz, R.B., Bravo, S.M., Klufas, R.A., Hsu, L., Barnes, P.D., Robson, C.D., and Antin, J.H. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. Am. J. Roentgenol. 165, 627-631 (1995).
64. Lorberboym, M., Bronster, D.J., Lidov, M., and Pandit, N. Reversible cerebral perfusion abnormalities associated with cyclosporine therapy in orthotopic liver transplantation. J. Nucl. Med. 37, 467-469 (1996).
65. Lanzino, G., Cloft, H., Hemstreet, M.K., West, K., Alston, S., and Ishitani, M. Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases. Clin. Neurol. Neurosurg. 99, 222-226 (1997).
66. Zimmer, W.E., Hourihane, J.M., Wang, H.Z., and Schriber, J.R. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. Am. J. Neuroradiol. 19, 601-608 (1998).
67. Garcia-Escrig, M., Martinez, J., Fernandez-Ponsati, J., Diaz, J., and Soto, O. Severe central nervous toxicity after chronic treatment with cyclosporine. Clin. Neuropharmacol. 17, 298-302 (1994).
68. Coley, S.C., Porter, D.A., Calamante, F., Chong, W.K., and Connely, A. Quantitative MR diffusion mapping and cyclosporine-induced neurotoxicity. Am. J. Neuroradiol. 20, 1507-1510 (1999).
69. De Bruijn, K.M., Slooff, M.J.H., Fockens, P., and Hillen, P.H. Cyclosporine neurotoxicity late after liver transplantation. Transplantation 47, 575-576 (1989).
70. Kurzendorf, U. Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 48, 531-532 (1989).
71. Warnecke, H., Schueler, S., Schiffka, J., and Hetzer, R. Neurological complications after heart transplantation: The influence of immunosuppression. Transplant. Proc. 19, 2510-2511 (1987).
72. Kahan, B.D. The synergistic effect of cyclosporine and sirolimus. Transplantation 63, 170 (1997).
73. Serkova, N., Klawitter, J., and Niemann, C.U. Organ-specific response to inhibition of mitochondrial metabolism by cyclosporine in the rat. Transpl. Int. 16, 748-755 (2003).
74. Kou, R., Greif, D., and Michel, T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J. Biol. Chem. 277, 29669-29673 (2002).
75. Beal, M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1366, 211-223 (1998).
76. Sengers, R.C.A., Stadhouders, A.M., and Trijbels, J.M.F. Mitochondrial myopathies. Eur. J. Pediatr. 141, 192-207 (1984).
77. DiMauro, S., Bonilla, E., Zaviani, M., Nakagawa, M., and DeVivo, D. Mitochondrial myopathies. Ann. Neurol. 17, 521-538 (1985).
78. Brockmann, K., Bjornstad, A., Dechent, P., Korenke, C. G., Smetitink, J., Trijbels, F., and Hanefeld, F. Succinate in dystrophic white matter: A proton magnetic resonance spectroscopy finding characteristic for complex II deficiency. Ann. Neurol. 52, 38-46 (2002).
79. 10. Ann. Neurol. 41, 160-165 (1997).
80. Nicholson, J.K., Lindon, J.C., and Holmes, E. "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate analysis of biologocal NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
81. Nicholson, J.K. and Wilson, I.D. Understanding "global" systems biology: Metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2, 668-676 (2003).
82. 1H-MRS metabonomics. Am. J. Transplant. submitted, (2004).
83. Serkova, N., Bendrick-Peart, J., Alexander, B., and Tissot van Patot, M.C. Metabolite concentrations in human term placentae and their changes due to delayed collection after delivery. Placenta 24, 227-235 (2003).
84. Christians, U., Gottschalk, S., Miljus, J., Hainz, C., Benet, L Z., Leibfritz, D., and Serkova, N. Alterations in glucose metabolism by cyclosporine link to oxidative stress in rat brain slices: Interactions with mTOR inhibitors. Br. J. Pharmacol. in press, (2004).
85. Jung, K. and Pergande, M. Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. FEBS Lett. 183, 167-169 (1985).
86. Rezzani, R., Rodella, L., and Bianchi, R. Early metabolic changes in peripheral blood cells of renal transplant recipients treated with cyclosporine A. Int. J. Immunopharmacol. 21, 455-462 (1999).
87. Higginson, J., Wackerhage, H., Woods, N., Schjerling, P., Ratkevicius, A., Grunnet, N., and Quistorff, B. Blockades of mitogen-activated protein kinase and calcineurin both change fibre-type markers in skeletal muscle culture. Pflugers Arch. 445, 437-443 (2002).
88. Okonkwo, D.O. and Povlishock, J.T. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J. Cereb. Blood Flow Metab. 19, 443-451 (1999).
89. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341, 233-249 (1999).
90. Bechstein, W.O. Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transplant Int. 13, 313-326 (2000).
91. Niemann, C.U., Saeed, M., Akbari, H., Jacobsen, W., Benet, L.Z., Christians, U., and Serkova, N. Close association between the reduction in myocardial energy metabolism and infarct size: Dose-response assessment of cyclosporine. J. Pharmacol. Exp. Ther. 302, 1123-1128 (2002).
92. Lensmeyer, G.L., Wiebe, D.A., Carlson, I.H., and Subramanian, R. Concentration of cyclosporine A and its metabolites in human tissues postmortem. J. Anal. Toxicol. 15, 110-115 (1991).
93. Serkova, N., Hausen, B., Berry, G.J., Jacobsen, W., Benet, L.Z., Morris, R.E., and Christians, U. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J. Pharmacol. Exp. Ther. 294, 323-332 (2000). blood level.